Last updated: February 7, 2023
Sponsor: Cairo University
Overall Status: Completed
Phase
2/3
Condition
Alopecia
Male Pattern Baldness
Hair Loss
Treatment
N/AClinical Study ID
NCT04481412
Cetirizine in alopecia
Ages 20-50 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Females with androgenetic alopecia of age 20-50 years.
- Patients experiencing active hair loss within the last 12 months.
- Sinclair scale 2, 3 and 4.
- Patients willing to continue their current regimen of vitamins and nutritionalsupplements and not start any new vitamins or nutritional supplements for the durationof the study.
- Patients willing to use a mild non-medicated shampoo and conditioner for the durationof the study.
- Patients who did not receive topical or systemic treatment for androgenetic alopeciaor prostaglandins in the last 6 months.
Exclusion
Exclusion Criteria:
- Patients with a chronic dermatological condition (eczema, psoriasis, infection,etc) of the scalp other than FPHL.
- Subjects who had hair transplants, scalp reduction, current hair weave or tattooingin the target area, which makes it difficult to perform hair count assessment.
- Subjects who received radiation therapy to the scalp, or has had chemotherapy inthe past year.
- Subjects who have a known underlying medical problem that could influence hairgrowth such as HIV infection, connective tissue disease, a thyroid condition,inflammatory bowel disease or other medical conditions, at the discretion of theinvestigator.
- Subjects with clinical diagnosis of alopecia areata or other non-AGA forms ofalopecia.
- Pregnant or lactating females or planning to become pregnant for the duration ofthe study.
- Patients with severe cardiovascular disease, uncontrolled or untreatedhypertension, arrythmia or clinically relevant hypotension.
- Subjects with hair loss for greater than 5 years, as medical therapy is unlikely tohave much effect at restoring hair follicles inactive for that long of a period.
- The subject has known hypersensitivity or previous allergic reaction to any of theactive or inactive components of the test articles.
- Patients using any medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone,testosterone, divalproex sodium) within the last 3 months.
Study Design
Total Participants: 66
Study Start date:
July 25, 2020
Estimated Completion Date:
November 30, 2021
Study Description
Connect with a study center
Al-Kasr Al-Ainy outpatient dermatology clinic
Cairo, ِAl-Kasr Al-Ainy 11559
EgyptSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.